How to Buy Weed in Switzerland: CBD Cannabis, THC Pilot Programs & What’s Actually Legal

Switzerland is taking an evidence-based approach to cannabis policy that’s drawing attention across Europe. Unlike countries that have either fully prohibited or commercialized cannabis, Switzerland has built a three-pathway system that balances public health, scientific research, and consumer access. For anyone looking to legally purchase cannabis in Switzerland in 2026, understanding these pathways (CBD cannabis, THC pilot programs, and medical cannabis) is essential. Whether you’re a resident or a visitor, Herb’s Dispensary Directory principles of local discovery apply globally, even in Switzerland’s unique regulatory landscape.

• Low-THC cannabis products with <1% THC are not subject to Switzerland’s Narcotics Act, though other product-category regulations still apply. CBD flowers intended for smoking with <1% THC can be sold and purchased legally. No prescription is needed.
• THC pilot programs are active in Zurich, Basel-Stadt, Basel-Landschaft, Bern, Biel, Lausanne, Vernier (Geneva canton), and Lucerne, but require canton residency and study enrollment
• Medical cannabis has been accessible since August 2022 through any licensed doctor’s prescription, without special authorization
• Switzerland’s 1% THC limit for legal CBD products is notably higher than the EU’s general hemp-cultivation threshold of 0.3%, though finished-product rules vary by EU country
• The Züri Can pilot has processed roughly 106,000 sales with 2,456 currently admitted participants
• Grashaus Projects reports positive effects on health protection, consumer competence, and combating the illicit market
• Nationwide legalization is under active discussion, with a draft law put into consultation in 2025, but it has not yet been enacted

Switzerland’s cannabis landscape in 2026 represents a unique middle ground between prohibition and full commercialization. The foundation of Swiss cannabis law rests on a key distinction: products containing less than 1% THC are not subject to the Narcotics Act, while those with higher THC content require participation in scientific pilot programs or a medical prescription.

This approach stems from Switzerland’s Narcotics Act and the Federal Office of Public Health’s (FOPH) focus on harm reduction rather than criminalization. The country has authorized multiple THC pilot programs across major cities since 2022, using them to gather real-world data on consumption patterns, public health impacts, and black market displacement before deciding on broader regulation.

The 2026 outlook is encouraging. Pilot programs are showing positive preliminary results, with roughly 10,500 participants enrolled across all trials, no observed increase in consumption, a trend toward lower-risk use, and no negative physical or mental health impacts in early data. The federal government is actively working on draft legislation for comprehensive cannabis reform, though the trials are still ongoing and serve as a basis for future policy decisions rather than settled conclusions.

For most people, including tourists and non-residents, CBD cannabis represents the simplest and most accessible pathway to legal cannabis in Switzerland. Since products must contain less than 1% THC, they won’t produce significant psychoactive effects but do offer the full spectrum of other cannabinoids and terpenes.

Switzerland’s 1% THC threshold is notably higher than the EU’s general hemp-cultivation threshold of 0.3%. (The older 0.2% figure you might see cited is outdated; the EU raised it.) This creates a more robust CBD market with products that retain more of the plant’s natural chemical profile, potentially enhancing therapeutic benefits through the entourage effect. That said, Swiss CBD products may not comply with the laws of neighboring countries, so exercise caution when traveling across borders, as finished-product rules vary by destination.

Key points about CBD purchases:

• Products must contain <1% THC, and the FOPH confirms that CBD flowers intended for smoking with <1% THC can be legally sold and purchased
• No prescription or registration is required for these products
• Products outside the “smokable flower” category (edibles, cosmetics, oils) may face additional product-specific regulations depending on how they’re classified (food, cosmetic, tobacco substitute, etc.)
• Always verify THC content through a Certificate of Analysis (COA), especially since even legal CBD can show up on drug tests due to trace THC levels

The Swiss CBD market has matured significantly, with options ranging from specialty shops to online retailers. Coop supermarkets currently carry CBD cannabis flowers in stores.

Green Passion, Zurich Green Passion’s Zurich store at Badenerstrasse 249 is a well-known CBD retail destination. The store offers:

• CBD flowers (with varying CBD potency, <1% THC) in Indoor, Greenhouse, and Outdoor varieties
• CBD hash, oils, vapes, edibles, and cosmetics
• Free nationwide shipping on orders over CHF 100
• All products lab-tested with certificates available

Other Options

• La Salade CBD in Interlaken offers Swiss-sourced CBD products
• Online retailers deliver nationwide with competitive pricing
• Local tobacco shops and some pharmacies in major cities

When shopping for CBD, always ask to see the COA to verify THC content and product quality.

Swiss CBD retailers offer a wide range of products:

• CBD Flowers: The most popular option, with varying CBD potency levels
• CBD Oils/Tinctures: Various concentrations (5%, 10%, 20%, 30%)
• CBD Hash: Concentrated extracts with enhanced effects
• CBD Vapes: Convenient and discreet consumption method
• CBD Edibles: Limited but growing selection of gummies and chocolates
• CBD Cosmetics: Topical applications for localized relief

For those interested in exploring similar products in other markets, Herb’s Products Catalog showcases the diversity of cannabis products available globally across categories like Flower, Oils, Edibles, and Vape Pens.

For Swiss residents living in specific cantons, THC pilot programs offer legal access to cannabis with full psychoactive potency. These aren’t commercial operations but scientific studies authorized by the FOPH to gather data on regulated cannabis markets. A 2021 amendment to the Narcotics Act created a ten-year framework for these limited pilot trials.

How THC Pilot Programs Work

Each pilot program operates as a controlled scientific study with strict participant requirements:

• Canton residency requirement: Must live in the canton where the pilot is conducted (not just the city)
• Age 18+: Standard age verification applies
• Current cannabis users: Programs are designed for people who already use cannabis and do not accept cannabis-naive individuals
• Health screening: Participants must pass medical questionnaires
• Study participation: Required to complete surveys and track consumption

Once enrolled, participants receive ID cards allowing them to purchase from authorized outlets. The FOPH confirms that each trial enforces a maximum monthly amount, though the specific limits vary by program.

Züri Can, Zurich Switzerland’s largest pilot program currently has 2,456 participants admitted and has processed roughly 106,000 sales. The study runs until October 2026 under the current FOPH approval, and the Zurich city council has requested an extension to October 2028. Züri Can operates through:

• 10 participating pharmacies in Zurich
• 9 currently active cannabis social clubs (the project started with 10)
• 1 Drug Information Centre (DIZ)

Cannabis Research Zurich Running parallel to Züri Can, this program targets 7,500 participants across multiple cities in the canton of Zurich (Zurich, Winterthur, Schlieren, Horgen, Wetzikon, Dübendorf). It runs from May 2024 to December 2028 and focuses on social and economic impacts with an integrated self-regulation education component.

Grashaus Projects, Basel-Landschaft This innovative program uses specialized retail stores (“Grashaus” meaning “grass house”) in Liestal and Allschwil rather than pharmacies, offering a more traditional cannabis retail experience. Running from November 2023 to October 2028, early findings report positive effects on health protection, consumer competence, and combating the illicit market.

Other Active Programs

• Weed Care (Basel-Stadt): Pharmacy-based model, one of Switzerland’s original pilots
• SCRIPT: Operating in Bern, Biel, and Lucerne through April 2026
• Cann-L: Active in Lausanne, running from July 2023 to June 2027 via a specialty store, with a planned enrollment of 1,600 participants
• La Cannabinothèque: Located in Vernier (Geneva canton), not in central Geneva

The enrollment process is broadly similar across programs:

1. Verify eligibility: Confirm you’re a resident of the canton running the program
2. Contact the program organizer: The FOPH recommends reaching out to the organizations running each trial directly for enrollment details
3. Complete screening: Fill out health questionnaires and provide residency proof
4. Await approval: Processing times vary by program
5. Receive participant ID: Required for all purchases
6. Shop at authorized outlets: Provided upon enrollment

Costs are intentionally set to roughly match the local black market and reflect THC strength, with monthly spending limits designed to prevent excessive consumption.

Since August 1, 2022, Switzerland has simplified medical cannabis access significantly. The prohibition on medical cannabis was removed, and any licensed doctor can now prescribe medical cannabis on a narcotics prescription without obtaining an exemption from the FOPH, making it far more accessible than in many other European countries.

Switzerland doesn’t maintain a fixed list of qualifying conditions. According to the FOPH, medical cannabis is used for symptoms such as chronic pain, muscle spasms, and unintentional weight loss, mainly when primary treatments are ineffective or as add-on therapy. Doctors assess each patient’s situation individually.

The prescription process involves:

1. Consultation with a qualified doctor (use Medcan’s provider directory)
2. Assessment of whether cannabis is appropriate for your specific condition
3. Prescription on official narcotics form specifying product and dosage
4. Dispensing at authorized pharmacies with narcotics handling licenses

Swiss medical cannabis includes several pharmaceutical-grade options:

• Sativex: THC/CBD mouth spray (approved for MS spasticity)
• Dronabinol: Synthetic THC capsules
• Magistral CBD formulations: Custom pharmacy-prepared oils for epilepsy
• Medical cannabis tinctures: Doctor-prescribed formulations

Cost and Insurance Coverage Unfortunately, general reimbursement by compulsory health insurance does not exist for medical cannabis. Exceptions may occur on a case-by-case basis, but these require formal applications to insurers with detailed medical justification. Most patients should expect to pay out of pocket.

The Medical Cannabis Association Switzerland (Medcan) provides the most comprehensive resource for finding qualified doctors and pharmacies nationwide, making it the essential starting point for anyone seeking medical cannabis access.

Cannabis access in Switzerland varies significantly by region.

High Coverage Areas: Zurich has the most robust access, with established CBD retail, dual pilot programs (Züri Can and Cannabis Research Zurich), and full medical access. The Basel region features both Weed Care (Basel-Stadt) and Grashaus Projects (Basel-Landschaft). Bern is served by the SCRIPT pilot alongside established CBD retail and medical access.

Moderate Coverage: Lausanne hosts the Cann-L pilot, and Vernier (Geneva canton) has La Cannabinothèque, in addition to CBD retail and medical access. Lucerne participates in the SCRIPT pilot.

Limited Coverage: Rural and mountain cantons rely primarily on online CBD delivery and medical access through Medcan’s provider network.

French-speaking regions (Geneva canton, Lausanne, Vaud) offer services in French, while German-speaking cities are the primary language zone. English is commonly spoken in major urban areas.

Based on positive early results from the pilot programs, Switzerland is actively moving toward broader cannabis regulation. In February 2025, a parliamentary committee adopted a draft law that was put into public consultation through December 1, 2025. However, this is a draft reform process, not enacted law, and the timeline for final passage remains uncertain.

Key features of the proposed framework include:

• Non-profit sales at the retail level
• For-profit cultivation and production allowed under federal authorization
• Home cultivation provisions
• Regulated retail outlets with strict quality controls
• Continued age verification and public health focus
• No commercial advertising to prevent youth targeting

This proposed model differs from North American commercial approaches by emphasizing non-profit retail distribution while still allowing licensed for-profit growing operations. The pilot programs continue to provide data that will inform the final legislative framework. It’s worth noting that the trials are still ongoing, and the FOPH describes them as a basis for future decisions, not a final proof of policy success.

For those wanting to stay updated on these developments and other global cannabis trends, Herb’s Newsletters provide bi-weekly cannabis updates including legalization news, top strains, and market developments.

While navigating Switzerland’s complex cannabis landscape requires understanding local laws and programs, Herb provides essential support for cannabis consumers worldwide through comprehensive education, product discovery, and community insights.

Herb’s unique value proposition goes beyond basic information aggregation with its science-backed, practical approach to cannabis education:

• Comprehensive Strain Knowledge: Explore detailed profiles in Herb’s Strain Guides to understand different cannabis varieties, effects, and terpene profiles that apply globally, including in Swiss pilot programs
• Product Discovery Platform: Herb’s Products Catalog showcases the full spectrum of cannabis products available worldwide, helping you understand what to look for in Swiss CBD shops or pilot program offerings
• Educational Resources: From beginner guides to advanced consumption techniques, Herb’s editorial content provides the foundational knowledge needed to make informed decisions in any cannabis market
• Global Cannabis News: Stay informed about international legalization trends and policy developments that could influence Switzerland’s ongoing reforms
• Community Insights: With 14 million community members, Herb provides access to collective wisdom and experiences that transcend geographic boundaries

Unlike generic information sources, Herb combines practical product discovery with deep educational content, helping you understand not just where to find cannabis products, but how to evaluate quality, understand effects, and maximize your cannabis experience safely and legally. For anyone exploring cannabis, whether in Switzerland’s unique regulatory environment or elsewhere, Herb’s comprehensive approach provides the tools and knowledge needed to navigate the cannabis landscape confidently.